Pfirzer and Merck Receive Key Regulatory Approvals

Now watching

Next video starts in : 7 Play

Pfirzer and Merck Receive Key Regulatory Approvals

Pfirzer and Merck Receive Key Regulatory Approvals
Replay video
Up next

Amazon Earnings Drive S&P 500, Nasdaq to All-Time Highs

Unlock your personal NFL Now stream by signing in to NFL.com

Pfirzer and Merck Receive Key Regulatory Approvals

by TheStreet 1:22 mins

Pfirzer and Merck Receive Key Regulatory Approvals

by TheStreet 1:22 mins

Shares of Pfizer and Merck are in the spotlight on Wednesday after both companies won some key federal regulatory approvals. Pfizer received the backing of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. The group gave Pfizer's Prevnar 13 vaccine approval for people ages 65 and older. Also, watch shares of Merck after it received approval to sell Belsomra, its treatment for insomnia. It's a new type of drug considered to have fewer side effects than older medications such as Ambien. The FDA cleared the sleeping pill in lower doses than what Merck had originally sought. Now, the DEA must determine restrictions on prescribing the medication before it can hit the market. Merck expects to start selling Belsomra late this year or early in 2015. TheStreet's Ruben Ramirez has details from New York.

TheStreet

Market Movers

  1. 14:30

    Nasdaq set to top record; Apple Watch deliveries; Comcast abandons merger

  2. 2:38

    Cablevision to offer 'cord cutters' package

  3. 3:40

    Comcast abandons Time Warner Cable merger

  4. 1:24

    Chipotle begins delivery

  5. 2:06

    Amazon hits new high; Google, Microsoft and Starbucks zoom higher

  6. 11:31

    Big earnings day; Facebook investors 'unlike'; cable merger woes